Fig. 5: 18F-fluciclovine uptake across tumour receptor subtypes.
From: Characterising 18F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging
a SUVmax, b SUVpeak, c K1 and d volume of distribution plotted for oestrogen receptor positive only (ER+), human epidermal growth factor receptor positive (HER2+) and triple-negative (TN) hormone receptor subtypes.
